Alfacalcidol: Difference between revisions
No edit summary |
Marked this version for translation |
||
Line 1: | Line 1: | ||
<languages /> | <languages /> | ||
<translate> | <translate> | ||
<!--T:1--> | |||
{{chembox | {{chembox | ||
| Verifiedfields = changed | | Verifiedfields = changed | ||
Line 87: | Line 88: | ||
}} | }} | ||
<!--T:2--> | |||
'''Alfacalcidol''' (or '''1-hydroxycholecalciferol''') is an analogue of [[vitamin D]] used for supplementation in humans and as a poultry feed additive. | '''Alfacalcidol''' (or '''1-hydroxycholecalciferol''') is an analogue of [[vitamin D]] used for supplementation in humans and as a poultry feed additive. | ||
<!--T:3--> | |||
Alfacalcidol has a weaker impact on [[calcium metabolism]] than [[calcitriol]]; but significant effects on the [[immune system]], including [[regulatory T cells]]. It is considered to be a more useful form of [[vitamin D]] supplementation, mostly due to much longer half-life and lower kidney load. It is the most commonly prescribed vitamin D metabolite for patients with [[end stage renal disease]], given that impaired renal function alters the ability to carry out the second [[hydroxylation]] step required for the formation of the physiologically active form of vitamin D, [[1,25-dihydroxyvitamin D3]]. Alfacalcidol is an active vitamin D3 metabolite, and therefore does not require the second [[hydroxylation]] step in the [[kidney]]. | Alfacalcidol has a weaker impact on [[calcium metabolism]] than [[calcitriol]]; but significant effects on the [[immune system]], including [[regulatory T cells]]. It is considered to be a more useful form of [[vitamin D]] supplementation, mostly due to much longer half-life and lower kidney load. It is the most commonly prescribed vitamin D metabolite for patients with [[end stage renal disease]], given that impaired renal function alters the ability to carry out the second [[hydroxylation]] step required for the formation of the physiologically active form of vitamin D, [[1,25-dihydroxyvitamin D3]]. Alfacalcidol is an active vitamin D3 metabolite, and therefore does not require the second [[hydroxylation]] step in the [[kidney]]. | ||
<!--T:4--> | |||
<!-- Society and culture --> | <!-- Society and culture --> | ||
It was patented in 1971 and approved for medical use in 1978. | It was patented in 1971 and approved for medical use in 1978. | ||
<!--T:5--> | |||
==Trade names== | ==Trade names== | ||
Pharmaceutical trade names include AlphaD and One-Alpha. | Pharmaceutical trade names include AlphaD and One-Alpha. | ||
<!--T:6--> | |||
==Other animals== | ==Other animals== | ||
Used as a poultry feed additive, it prevents [[tibial dyschondroplasia]] and increases [[phytate]] [[bioavailability]]. | Used as a poultry feed additive, it prevents [[tibial dyschondroplasia]] and increases [[phytate]] [[bioavailability]]. | ||
<!--T:7--> | |||
{{Vitamins}} | {{Vitamins}} | ||
{{Vitamin D receptor modulators}} | {{Vitamin D receptor modulators}} | ||
<!--T:8--> | |||
{{二次利用|date=13 December 2023}} | {{二次利用|date=13 December 2023}} | ||
[[Category:Secosteroids]] | [[Category:Secosteroids]] |